Medicine

Publisher Adjustment: Allogeneic CD5-specific CAR-T treatment for relapsed\/refractory T-ALL: a phase 1 trial

.Attributes Medication, Released online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Improvement: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a phase 1 trial.

Articles You Can Be Interested In